Pharmacist intervention for glycaemic control in the community (the RxING study)

Yazid N Al Hamarneh, Theresa Charrois, Richard Lewanczuk, Ross T Tsuyuki, Yazid N Al Hamarneh, Theresa Charrois, Richard Lewanczuk, Ross T Tsuyuki

Abstract

Objective: To determine the effect of a community pharmacist prescribing intervention on glycaemic control in patients with poorly controlled type 2 diabetes.

Design: Pragmatic, before-after design.

Setting: 12 community pharmacies in Alberta, Canada.

Participants: Type 2 diabetes receiving oral hypoglycaemic medications and with glycated haemoglobin (HbA1c) of 7.5-11%.

Intervention: Pharmacists systematically identified potential candidates by inviting patients with type 2 diabetes to test their HbA1c using validated point-of-care technology. Pharmacists prescribed 10 units of insulin glargine at bedtime, adjusted by increments of 1 unit daily to achieve a morning fasting glucose of ≤5.5 mmol/L. The patients were followed up at 2, 4, 8, 14, 20 and 26 weeks.

Primary outcome: Change in HbA1c from baseline to week 26.

Secondary outcomes: Proportion of patients achieving target HbA1c, changes in oral hypoglycaemic agents, quality of life and patient satisfaction, persistence on insulin glargine, number of insulin dosage adjustments per patient and number of hypoglycaemic episodes.

Results: We screened 365 patients of whom 111 were eligible. Of those, 100 (90%) were enrolled in the study; all 11 patients who did not consent refused to use insulin. Average age was 64 years (SD 10.4), while average diabetes duration was 10.2 years (SD 7). HbA1c was reduced from 9.1% (SD 1) at baseline to 7.3% (SD 0.9); a change of 1.8% (95% CI 1.4 to 2, p<0.001). Fasting plasma glucose was reduced from 11 (SD 3.3) to 6.9 mmol/L (SD 1.8); a change of 4.1 mmol/L (95% CI of 3.3 to 5, p=0.007). Fifty-one per cent of the patients achieved the target HbA1c of ≤7% at the end of the study.

Conclusions: This is the first completed study of independent prescribing by pharmacists. Our results showed similar improvements in glycaemic control as previous physician-led studies. RxING provides further evidence for the benefit of pharmacist care in diabetes.

Trial registration: clinicaltrials.gov; Identifier: NCT01335763.

Keywords: Diabetes; HbA1c; Pharmacist; insulin glargine.

Figures

Figure 1
Figure 1
Patients’ screening and enrolment flow chart.
Figure 2
Figure 2
Intervention effect on glycated haemoglobin in patients with uncontrolled type 2 diabetes (n=100).
Figure 3
Figure 3
Intervention effect on fasting plasma glucose in patients with uncontrolled type 2 diabetes (n=100).

References

    1. World Health Organization Diabetes. 2012. (accessed Feb 2013)
    1. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence and mortality in Ontario, Canada 1995–2005: a population based study. Lancet 2007;369:750–6
    1. World Health Organization Diabetes: the cost of diabetes. 2012. (accessed Feb 2013)
    1. Al Hamarneh YN, Rosenthal M, Tsuyuki RT. Glycemic control in community-dwelling patients with type 2 diabetes. Can Pharm J 2012;2:68–9 e1
    1. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999;7:139–53
    1. Polonsky WH, Jackson RA. What's so tough about taking insulin? Clin Diabetes 2004;22:147–50
    1. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT study. Diabet Med 2006;23:736–42
    1. Canadian Diabetes Association Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:s1–201
    1. Harris S, Yale JF, Dempsey E, et al. Can family physicians help patients initiate basal insulin therapy successfully? Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: Lessons for family practice from Canadian INSIGHT trial. Can Fam Physician 2008;54:550–8
    1. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 2005;28:2543–5
    1. Shiu JR, Simpson SH, Johnson JA, et al. Quantifying opportunities to affect diabetes management in the community. Can Pharm J 2006;139:37–8
    1. O'Donovan D, Byrne S, Sahm L. The role of pharmacists in control and management of type 2 diabetes mellitus; a review of the literature. J Diabetol 2011;1:5–21
    1. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy 2008;28:421–36
    1. Armour CL, Taylor SJ, Houriham F, et al. Implementation and evaluation of Australian pharmacists’ diabetes care services. J Am Pharm Assoc 2004;44:455–66
    1. Fornos JA, Andres NF, Andres JC, et al. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci 2006;28:65–72
    1. Krass I, Armour CL, Mitchell B, et al. The pharmacy diabetes care program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med 2007;24:677–83
    1. Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 2007;1:540–8
    1. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life and adherence. Clin Med Res 2008;6:54–67
    1. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine in type 2 diabetes. Diabetes Care 2005;28:950–5

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever